Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma

Shebli Atrash, Syed Abbas Ali, Saad Z. Usmani

Research output: Contribution to journalReview articlepeer-review

Abstract

Relapsed/refractory multiple myeloma (MM) remains a significant clinical challenge, despite a wide array of approved therapeutic agents. Immunotherapy offers an advantage in this setting. Chimeric antigen receptor (CAR) modified T-cells have transformed care for patients with hematologic malignancies. CAR-T cells targeting CD-19 B-cell lymphoma cells have shown prominent activity in lymphoma and acute lymphoblastic leukemia. Recently, the CAR-T cell platform for MM demonstrated therapeutic benefit. Hence, it is rapidly progressing. The most commonly tested target for MM is the B-cell maturation antigen. Complexities involved in the generation and use of CAR-T cells for MM include the identification of appropriate target antigens that are specific, and tumor type restricted, in addition to the optimization of CAR constructs to mitigate toxicities including cytokine release syndrome. CAR-T cells hold immense promise as a therapeutic modality for the treatment of MM. In this article, we provide an updated review of clinical trials of MM-specific CAR-T cells.

Original languageEnglish (US)
Pages (from-to)21-34
Number of pages14
JournalClinical Lymphoma, Myeloma and Leukemia
Volume21
Issue number1
DOIs
StatePublished - Jan 2021

Keywords

  • BCMA targets
  • Cytokine release syndrome
  • Refractory
  • Relapsed
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma'. Together they form a unique fingerprint.

Cite this